Werfen Displays Complete Solutions for Hemostasis, Acute Care, Transfusion, and Transplant Solutions
Werfen is highlighting a broad portfolio of instruments, reagents, automation, and digital solutions for hemostasis, acute care, transfusion medicine, autoimmunity, and transplant diagnostics. More...28 Jul 2026
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hematology Consumables
Bioblood Devices
Immunofluorescence Analyzer
IFA System
In Other News
Roche Highlights Intelligent Lab Solutions and High-Precision Instruments at ADLM 2026
Cepheid Unveils Third-Generation GeneXpert System at ADLM 2026
Ozelle Presents AI-Powered O-Cyte 1 Hematology Analyzer
bioMérieux Showcases Latest Diagnostic Innovations at ADLM 2026
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Tactus AI Unveils Humanoid Assistant for Clinical Laboratory Bench Work
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Cepheid Presents Third-Generation GeneXpert System at ADLM 2026
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Blood Gene Expression Fluctuates More Than Expected Over Time
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
ADLM 2026 Explores Diabetes Milestones, Space Diagnostics, Alzheimer’s–Down Syndrome Links, and Cancer Advances
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
